Ikena Oncology gets FDA fast track designation for IK-930 in mesothelioma
Ikena Oncology has secured fast track designation for IK-930 from the US Food and Drug Administration in the treatment of unresectable NF2-deficient malignant pleural mesothelioma. IK-930 is a TEAD inhibitor designed to target the Hippo signaling pathway. Earlier this year, IK-930 was granted the FDA orphan drug designation for the treatment of patients having malignant […]